Delta-Fly Pharma, Inc.
4598.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥5 | ¥4 | ¥3 | ¥3 |
| - Cash | ¥0 | ¥1 | ¥1 | ¥1 |
| + Debt | ¥0 | ¥0 | ¥0 | ¥0 |
| Enterprise Value | ¥5 | ¥3 | ¥3 | ¥2 |
| Revenue | ¥0 | ¥0 | ¥0 | ¥0 |
| % Growth | – | – | -100% | – |
| Gross Profit | -¥0 | -¥0 | -¥0 | ¥0 |
| % Margin | – | – | – | 100% |
| EBITDA | -¥2 | -¥1 | -¥1 | -¥1 |
| % Margin | – | – | – | -320% |
| Net Income | -¥2 | -¥1 | -¥1 | -¥1 |
| % Margin | – | – | – | -322.4% |
| EPS Diluted | -195.58 | -198.78 | -234.51 | -178.58 |
| % Growth | 1.6% | 15.2% | -31.3% | – |
| Operating Cash Flow | -¥2 | -¥1 | -¥1 | -¥1 |
| Capital Expenditures | -¥0 | -¥0 | -¥0 | ¥0 |
| Free Cash Flow | -¥2 | -¥1 | -¥1 | -¥1 |